|
By
Marilyn Mullen
|
|
Tuesday, 05 May 2015 01:16 |
 Biopharmaceutical research and development firm, CytRx Corporation (NASDAQ:CYTR), specializing in oncology, has confirmed an interim analysis from the two ongoing phase 1b aldoxorubicin combination studies combining aldoxorubicin with either gemcitabine or ifosfamide.
|
|
Read more...
|
|
By
William Kent
|
|
Friday, 01 May 2015 18:38 |
 Undisputed leader in hepatitis C drugs market, Gilead Sciences, Inc. (NASDAQ:GILD), has come out with first-quarter financial results for the year.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Wednesday, 29 April 2015 16:54 |
 Merck & Co., Inc.(NYSE:MRK) has confirmed that The Lancet and Clinical Infectious Diseases published online results from pivotal Phase 3 clinical studies of ZERBAXA for Injection in complicated urinary tract infections as well as complicated intra-abdominal infections.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Tuesday, 28 April 2015 13:47 |
|
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has confirmed receiving the much waited Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for the Vascepa capsules ANCHOR trial supplemental New Drug Application (sNDA).
|
|
Read more...
|
|
By
Mary Davila
|
|
Monday, 27 April 2015 18:41 |
 Celladon Corp (NASDAQ:CLDN)’s shares plunged over 80% after the company said that the Phase 2b CUPID2 trial doesn’t meet primary as well as secondary endpoints.
|
|
Read more...
|
|
By
Marilyn Mullen
|
|
Friday, 24 April 2015 14:24 |
 GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed that U.S. Food and Drug Administration has given orphan drug designation to the Cannabidiol (CBD) for using in treatment of newborn children having neonatal hypoxic-ischemic encephalopathy (NHIE).
|
|
Read more...
|
|
By
David Fowler
|
|
Thursday, 23 April 2015 13:57 |
|
Gilead Sciences, Inc. (NASDAQ:GILD) has confirmed pre-clinical data as well as results from Phase 1 and Phase 2 studies which demonstrate development of an investigational all-oral as well as pan-genotypic regimen of Sovaldi. Sovaldi is the investigational NS5A inhibitor GS-5816 and GS-9857.
|
|
Read more...
|
|
By
David Fowler
|
|
Wednesday, 22 April 2015 17:33 |
 Molecular diagnostics company, Great Basin Scientific Inc. (NASDAQ:GBSN), has got clearance from U.S. Food and Drug Administration for the molecular diagnostic test for Group B Streptococcus (GBS).
|
|
Read more...
|
|
By
William Kent
|
|
Tuesday, 21 April 2015 14:24 |
|
Clinical-stage pharmaceutical firm, Calithera Biosciences Inc. (NASDAQ:CALA), has confirmed the preclinical data for the main anti-cancer therapeutic candidate, CB-839.
|
|
Read more...
|
|
By
William Kent
|
|
Monday, 20 April 2015 13:52 |
 The Medicines Company (NASDAQ:MDCO)’s shares tumbled over 5% despite the company said that U.S. Food and Drug Administration has given approval to a supplemental new drug application (sNDA) for the fresh formulation of MINOCIN for Injection.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 6 of 12 |
